Print

Featured Studies Results

Cancer: Breast | Study Type: Treatment

Studies for People with ER-Positive, HER2-Negative Advanced or Metastatic Breast Cancer (TACTIVE-U)

https://www.facingourrisk.org/research-clinical-trials/study/279/treatment-studies-for-people-with-er-positive-her2-negative-advanced-or-metastatic-breast-cancer-tactive-u

Treatment
Treatment for ER-positive, HER2-negative metastatic breast cancer


Studies for People With ER-Positive, HER2-Negative Advanced or Metastatic Breast Cancer (VERITAC Studies)

https://www.facingourrisk.org/research-clinical-trials/study/269/studies-for-people-with-er-positive-her2-negative-advanced-or-metastatic-breast-cancer-veritac-studies

Treatment
Treatment studies for ER-positive, HER2-negative metastatic breast cancer


Combining the Immunotherapy Dostarlimab and PARP Inhibitor Niraparib for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with an Inherited or Tumor BRCA Mutation

https://www.facingourrisk.org/research-clinical-trials/study/231/immunotherapy-and-parp-inhibitor-for-advanced-or-metastatic-breast-ovarian-or-pancreatic-cancer-with-a-brca-mutation

Clinicaltrials.gov identifier:
NCT04673448 (https://clinicaltrials.gov/show/NCT04673448)

Treatment
Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation


Testing a Vaccine for Treating or Preventing Triple-Negative Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/285/

Clinicaltrials.gov identifier:
NCT04674306 (https://clinicaltrials.gov/show/NCT04674306)

Treatment
Treatment study for people with stage 2 or 3 triple-negative breast cancer at high risk for recurrence.


Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)

https://www.facingourrisk.org/research-clinical-trials/study/282/study-of-the-parp-inhibitor-azd9574-alone-and-combined-with-other-cancer-medicines-to-treat-people-with-advanced-solid-cancers-certis1-study

Clinicaltrials.gov identifier:
NCT05417594 (https://clinicaltrials.gov/show/NCT05417594)

Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas


A Randomized Study of Robotic-Assisted Nipple Sparing Mastectomy vs. Standard Surgery Nipple Sparing Mastectomy for Early Stage Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/263/a-randomized-study-of-robotic-assisted-nipple-sparing-mastectomy-vs-open-surgery-nipple-sparing-mastectomy-for-early-stage-breast-cancer

Clinicaltrials.gov identifier:
NCT05720039 (https://clinicaltrials.gov/show/NCT05720039)

Treatment
Nipple sparing mastectomy with reconstruction for women with early-stage breast cancer


TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

https://www.facingourrisk.org/research-clinical-trials/study/262/tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer

Clinicaltrials.gov identifier:
NCT02693535 (https://clinicaltrials.gov/show/NCT02693535)

Treatment
Cancer treatment study for people with advanced solid tumors


Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

https://www.facingourrisk.org/research-clinical-trials/study/230/treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib

Clinicaltrials.gov identifier:
NCT04550494 (https://clinicaltrials.gov/show/NCT04550494)

Treatment
Treatment study for people with advanced solid tumors


NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/204/nuv-868-alone-and-in-combination-with-parp-inhibitors-in-patients-with-advanced-solid-tumors

Clinicaltrials.gov identifier:
NCT05252390 (https://clinicaltrials.gov/show/NCT05252390)

Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer


SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells

https://www.facingourrisk.org/research-clinical-trials/study/117/sharon-a-clinical-trial-for-metastatic-cancer-with-an-inherited-brca-or-palb2-mutation-using-chemotherapy-and-patients-own-stem-cells

Clinicaltrials.gov identifier:
NCT04150042 (https://clinicaltrials.gov/show/NCT04150042)

Treatment
Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation


Treating Early-Stage HER2-Negative Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/158/treating-early-stage-breast-cancer-with-a-parp-inhibitor-niraparib-and-immunotherapy-dostarlimab-in-people-with-a-brca-or-palb2-mutation

Clinicaltrials.gov identifier:
NCT04584255 (https://clinicaltrials.gov/show/NCT04584255)

Treatment
Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation


Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)

https://www.facingourrisk.org/research-clinical-trials/study/176/investigational-parp-inhibitor-azd5305-alone-or-combined-with-other-anti-cancer-agents-in-people-with-advanced-solid-tumors-petra

Clinicaltrials.gov identifier:
NCT04644068 (https://clinicaltrials.gov/show/NCT04644068)

Treatment
Advanced ovarian, breast, prostate or pancreatic cancer


Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/157/treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors

Clinicaltrials.gov identifier:
NCT04657068 (https://clinicaltrials.gov/show/NCT04657068)

Treatment
Advanced solid tumors


Testing the New Targeted Therapy CYH33 in Combination With the PARP Inhibitor Olaparib in People With Advanced Solid Tumors and DNA Damage Repair Mutations

https://www.facingourrisk.org/research-clinical-trials/study/168/cyh33-in-combination-with-olaparib-in-patients-with-advanced-solid-tumors-and-dna-damage-repair-mutations

Clinicaltrials.gov identifier:
NCT04586335 (https://clinicaltrials.gov/show/NCT04586335)

Treatment
Advanced solid tumors


A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)

https://www.facingourrisk.org/research-clinical-trials/study/68/olaparib-expanded-treating-metastatic-breast-cancer-in-people-without-gbrca-mutations

Clinicaltrials.gov identifier:
NCT03344965 (https://clinicaltrials.gov/show/NCT03344965)

Treatment


Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations

https://www.facingourrisk.org/research-clinical-trials/study/100/talazoparib-for-people-with-metastatic-breast-cancer-who-have-acquired-somatic-brca-mutations

Clinicaltrials.gov identifier:
NCT03990896 (https://clinicaltrials.gov/show/NCT03990896)

Treatment


A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/102/a-randomized-study-of-an-ehealth-delivery-alternative-for-cancer-genetic-testing-for-hereditary-predisposition-in-metastatic-breast-ovarian-prostate-and-pancreatic-cancer-patients-e-reach

Clinicaltrials.gov identifier:
NCT04353973 (https://clinicaltrials.gov/show/NCT04353973)

Treatment


Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive nodal Radiation: A Radiotherapy Comparative Effectiveness Trial

https://www.facingourrisk.org/research-clinical-trials/study/56/radcomp-a-study-at-the-heart-of-breast-cancer-treatment

Clinicaltrials.gov identifier:
NCT02603341 (https://clinicaltrials.gov/show/NCT02603341)

Treatment


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.